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Abstract Taurine (2-aminoethanesulfonic acid) is the
most abundant free amino acid in humans and plays an
important role in several essential biological processes
such as bile acid conjugation, maintenance of calcium
homeostasis, osmoregulation and membrane stabilization.
Moreover, attenuation of apoptosis and its antioxidant
activity seem to be crucial for the cytoprotective effects of
taurine. Although these properties are not tissue specific,
taurine reaches particularly high concentrations in tissues
exposed to elevated levels of oxidants (e.g., inflammatory
cells). It suggests that taurine may play an important role in
inflammation associated with oxidative stress. Indeed, at
the site of inflammation, taurine is known to react with and
detoxify hypochlorous acid generated by the neutrophil
myeloperoxidase (MPO)–halide system. This reaction
results in the formation of less toxic taurine chloramine
(TauCl). Both haloamines, TauCl and taurine bromamine
(TauBr), the product of taurine reaction with hypobromous
acid (HOBr), exert antimicrobial and anti-inflammatory
properties. In contrast to a well-documented regulatory role
of taurine and taurine haloamines (TauCl, TauBr) in acute
inflammation, their role in the pathogenesis of inflamma-
tory diseases is not clear. This review summarizes our
current knowledge concerning the role of taurine, TauCl
and TauBr in the pathogenesis of inflammatory diseases
initiated or propagated by MPO-derived oxidants. The aim
of this paper is to show links between inflammation,
neutrophils, MPO, oxidative stress and taurine. We will
discuss the possible contribution of taurine and taurine
haloamines to the pathogenesis of inflammatory diseases,
especially in the best studied example of rheumatoid
arthritis.
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Introduction
Acute inflammation is a physiological response of tissues
to harmful stimuli such as pathogens, damaged cells or
cancer cells and irritants. This response, mediated pre-
dominantly by innate immunity, is responsible for elimi-
nation of these injurious stimuli and for the subsequent
healing process. The major cells involved in acute
inflammation are neutrophils: phagocytes responsible for
microbial killing and for generation of various proinflam-
matory mediators. The myeloperoxidase–halide system
plays a unique role in killing pathogens phagocytosed by
neutrophils (Klebanoff 1968, 2005) through generation of
hypochlorous acid (HOCl), a potent microbicidal and
cytotoxic oxidant (Thomas 1979). Remarkably, MPO is the
only mammalian enzyme that oxidizes Cl- into HOCl
(Gaut et al. 2001). Moreover, MPO can also oxidize Br- to
produce hypobromous acid (HOBr) (Thomas et al. 1995).
Upon contact with a pathogen, activated phagocytes (both
neutrophils and macrophages) produce a respiratory burst
characterized by intense uptake of oxygen. Oxidant pro-
duction begins when a membrane-associated NADPH
oxidase reduces molecular oxygen to superoxide, which
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then yields H2O2. In neutrophil phagolysosomes, myelo-
peroxidase (MPO) uses H2O2 to convert chloride ion to
HOCl, or bromide ion to HOBr (Klebanoff 1968; Thomas
1979; Henderson et al. 2001)
Cl + H2O2 + Hþ ! HOCl + H2O,
Br + H2O2 + Hþ ! HOBr + H2O:
Both hypohalous acids, HOCl and HOBr, are
components of innate immunity and protect the host from
infections by using their oxidizing potential to kill
pathogens, but they may also damage host tissue. The
microbicidal effects of HOCl have been linked to oxidation
of methionine residues in bacterial cytosolic and inner
membrane proteins (Rosen et al. 2009). On the other
hand, overproduction of these oxidants and insufficient
neutralization by antioxidants may lead to the development
of oxidative stress and chronic inflammation (Smith
1994; Weiss 1988). Such a scenario may contribute to
pathogenesis of inflammatory diseases, in which the
neutrophil MPO–halide system is involved (Fig. 1). The
above information clearly suggests that antioxidants play a
crucial role in maintaining homeostasis and in amelioration
of the harmful effect of oxidative stress. We asked the
question whether taurine and/or taurine haloamines play a
role in the pathogenesis of inflammatory diseases. We will
focus on the role of TauCl in the regulation of inflammation
in rheumatoid arthritis, the best studied diseases in our
laboratories (Marcinkiewicz and Kontny 2012).
Taurine links to inflammation and oxidative stress
Taurine, a semi-essential sulfur-containing b-amino acid, is
present at high concentrations in most cells of all animal
species (Sturmann 1993). In humans, taurine is formed
from methionine and cysteine metabolism via hypotaurine
in hepatocytes. Other cells (e.g., neutrophils) contain very
high concentrations of taurine due to taurine uptake from
the blood, a source of both endogenous and diet taurine
(Fig. 2) (Bouckenooghe et al. 2006).
Taurine tissue distribution is characterized by low con-
centrations of taurine in the plasma and extracellular fluids
(ranging from 10 to 100 lM) and high intracellular con-
centrations of taurine reaching up to 50 mM, depending on
the cell type (Huxtable 1992; Learn et al. 1990). The bio-
synthetic capacity of humans to produce taurine is limited
in neonates (the effect amplified by prematurity) and also
declines with aging and some pathological stages (trauma,
sepsis). In these situations, the diet is likely to be an
important taurine source (Redmond et al. 1998).
The high taurine levels in phagocytes and accumulation
in taurine inflammatory lesions suggests its role in innate
immunity (Schuller-Levis and Park 2004). Activated
phagocytes generate a variety of microbicidal and toxic
oxidants produced by the peroxidase system in these cells.
As taurine is present at high concentrations in leukocytes,
one may hypothesise that taurine deficiency will affect the
immune cell functions. Indeed, prolonged taurine defi-
ciency in cats leads to profound abnormalities in the
immune system including significant leukopenia, a
decreased respiratory burst in neutrophils and depletion of
cells from B cell areas of lymph nodes and spleen
(Schuller-Levis et al. 1990). However, there is no clear
evidence concerning the association between taurine defi-
ciency and a defect of the immune system in humans. On
the other hand, it is commonly accepted that taurine plays
an important role in the immune system as an antioxidant
to protect cells, including leukocytes, from oxidative stress
(Schaffer et al. 2009; Wang et al. 2009). Therefore, the
Fig. 1 Hypohalous acids, the major products of PO–halide system
exert both a beneficial (microbicidal) and detrimental (tissue injury)
role in neutrophil-associated inflammation
Fig. 2 Fate of endogenous and diet taurine in activated neutrophils
8 J. Marcinkiewicz, E. Kontny
123
primary role of taurine is cytoprotection and maintaining
homeostasis of cells involved in acute and chronic
inflammatory/oxidative stress (Fig. 3).
Oxidative stress is a major factor responsible for tissue
damage in conditions such as infection, acute and chronic
inflammation, cancer and aging. At a site of inflammation,
oxidative stress is mediated by reactive oxygen species
(ROS) generated primarily by activated leukocytes (neu-
trophils, macrophages, eosinophils). ROS play a beneficial
role in host defense against pathogens, but they are also
responsible for tissue injury (Weiss 1988; Smith 1994). A
variety of antioxidants are involved in the prevention of
oxidant-induced cell damage and reduction of oxidative
modification of self-molecules, primarily high molecular
compounds such as lipids, proteins and DNA. Antioxidants
(the antioxidant network) act through one of three mech-
anisms: (1) reduction of ROS generation, (2) neutralization
of ROS and (3) interference with the action of ROS
(Schaffer et al. 2009).
Taurine is found at particularly high concentrations in
tissues exposed to elevated levels of oxidants, suggesting
its role in the attenuation of oxidative stress (Green et al.
1991; Jeon et al. 2009; Oliveira et al. 2010). Indeed, there
have been numerous reports indicating taurine as an
effective antioxidant, but the mechanism underlying its
antioxidant activity remains unclear. The best established
antioxidant action of taurine is neutralization of hypo-
chlorous acid (HOCl), an extremely toxic oxidant gener-
ated by the MPO–halide system (Weiss et al. 1982). This
activity explains the anti-inflammatory properties of tau-
rine, as its reaction with HOCl results in generation of
taurine chloramine (TauCl), a more stable and less toxic
anti-inflammatory mediator (Weiss et al. 1982; Thomas
1979) (Fig. 4).
Therefore, taurine may be considered the component of
innate immunity with a special impact on the development
of acute inflammation. However, not all of the antioxidant
actions of taurine are related to HOCl, because they can
occur in systems lacking neutrophils. Although taurine is
incapable of directly scavenging classical ROS, it has been
suggested that it is an effective inhibitor of ROS genera-
tion. It has been shown that taurine enhances expression
and activities of antioxidant enzymes, such as superoxide
dismutase, catalase and glutathione peroxidase (Jang et al.
2009).
In conclusion, the data presented above suggest that the
major role of taurine in the immune system is associated
with taurine’s antioxidant properties, namely, with its ability
to react with HOCl or HOBr to generate the biologically
active but less toxic mild oxidants taurine chloramine
(TauCl) and taurine bromamine (TauBr), respectively
Taurine + HOCl ! taurine chloramine + H2O,
Taurine + HOBr ! taurine bromamine + H2O:
Taurine haloamines (TauCl, TauBr): a role in host
defense
TauCl and TauBr antimicrobial capacity
It is well known that oxidants generated by phagocytes at a
site of inflammation are involved in host defense against
microbes. Among them, hypohalous acids (HOCl, HOBr),
extremely strong microbicidal agents, play a crucial role
in killing of pathogens by neutrophils and eosinophils.
They can kill a wide spectrum of Gram-positive and
Gram-negative bacteria, fungi (yeast and molds), viruses,
protozoa and worm larvae (Klebanoff 1968; Weiss 1988;
Thomas et al. 1995). TauCl and TauBr, the physiological
Fig. 3 Biological functions of intracellular taurine and the immune
cells
Fig. 4 Targets of HOCl at a site of inflammation and its interaction
with taurine. Inside phagolysosomes, HOCl kills ingested microbes.
Outside phagolysosomes, taurine neutralizes detrimental effects of
HOCl on neighboring cells and protects ‘‘self’’ molecules from
oxidative modification. TauCl, the product of this reaction, is less
toxic than HOCl. TauCl is not membrane permeable, oxidizes distinct
targets and causes less damage to biologically active molecules
(Marcinkiewicz and Kontny 2012)
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products of the MPO–halide system, show bactericidal,
fungicidal, antiviral and antiparasitic properties, as dem-
onstrated in vitro in a number of papers (Nagl et al. 2000b,
2001; Gottardi et al. 2005; Marcinkiewicz et al. 2000,
2006a; Yazdanbakhsh et al. 1987).
TauCl, the product of activated neutrophils, reaches
micromolar concentrations (\100 lM) at the site of
inflammation. At these physiological concentrations and at
neutral pH, TauCl shows very weak antimicrobial activity.
However, in acidic milieu which is typical for an inflam-
matory environment (pH 4–6), the ability of TauCl to kill
pathogens increases significantly due to formation of the
more potent TauCl2 (taurine dichloramine). TauCl2 is more
bactericidal than TauCl, especially against Gram-negative
bacteria, probably due to better penetration into bacteria. In
addition, transfer of the active chlorine (transchlorination)
from TauCl to amino groups of other molecules enhances
its activity, mainly because of the formation of mono-
chloramine (NH2Cl) (Gottardi et al. 2005; Gottardi and
Nagl 2010; Nagl et al. 2003). However, it has not been
proven whether endogenous TauCl also contributes to the
killing of microbes in vivo. On the other hand, exogenous
TauCl proved to be extremely well tolerated by human
tissues and even 1 % aqueous solution of TauCl may be
applied locally in the treatment of some skin and mucous
infections (Gottardi and Nagl 2010).
TauBr, in contrast to TauCl, seems to be an effective
microbicidal agent at very low physiologic concentrations
\10 lM, even at neutral pH (Marcinkiewicz et al. 2006a,
b). These results suggest that TauBr may contribute to host
defense against microbes, although this still needs to be
confirmed in vivo.
Importantly, the data investigating TauCl and TauBr
antimicrobial activity in vitro have all been collected using
planktonic form of bacteria, but not sessile bacteria hidden
in a biofilm. Recently, there has been a tremendous interest
in the role of biofilms in chronic infectious diseases and in
the resistance of biofilms to antibiotics, disinfectants and
phagocytosis (Costeron et al. 1991). As microbial biofilms
are the most common mode of growth of bacteria and fungi
in nature (O’Toole et al. 2000), it is reasonable to study
whether TauCl and TauBr are able to kill bacteria hidden in
a biofilm or destroy a protective exopolymeric matrix of
growing biofilms. Our preliminary data suggest that taurine
haloamines, especially TauBr, are promising candidates in
the local therapy of biofilm-associated infections such as
chronic sinusitis, otitis media, acne vulgaris and peri-
odontal diseases.
Anti-inflammatory properties of TauCl and TauBr
Acute inflammation is characterized by a massive neutro-
phil infiltration and generation of a variety of inflammatory
mediators such as cytokines, eicosanoids and ROS (Weiss
1988; Thomas 1979). Studies from many laboratories have
demonstrated that taurine haloamines (TauCl, TauBr) exert
both bactericidal and anti-inflammatory properties (Park
et al. 1993, 1995; Marcinkiewicz et al. 1995b, 1998, 2000,
2005; Quinn et al. 2003; Kim et al. 1996; Kim and Cha
2009). Taurine haloamines inhibit the production of pro-
inflammatory cytokines (TNF-a, IL-1b and IL-6) (Mar-
cinkiewicz et al. 1995a; Park et al. 1997; Barua et al.
2001). Moreover, it has been shown that TauCl reduces the
production of nitric oxide (NO) and prostaglandin E2
(PGE2) and decreases the activity of matrix metallopro-
teinases (Chorazy-Massalska et al. 2004; Park et al. 2000;
Kim et al. 2007). The above-mentioned anti-inflammatory
properties together with the capacity of TauCl to induce
leukocyte apoptosis suggest that TauCl may be involved in
the resolution and termination of acute inflammation
(Klamt and Shacter 2005). Interestingly, taurine, in contrast
to TauCl, protects cells from apoptosis as shown in a
number of in vitro studies (Jong et al. 2011; Maher et al.
2005).
Impact of TauCl and TauBr on the induction
of antioxidant network
It is well documented that taurine protects cells against
oxidative injury (Schaffer et al. 2009). In acute inflam-
mation, which is characterized by neutrophil infiltration
and generation of ROS by the MPO–halide system, taurine
antioxidant activity is primarily related to the neutraliza-
tion of HOCl and HOBr, as described above. It is also well
known that TauCl and TauBr, apart from antimicrobial and
anti-inflammatory properties, may also show antioxidant-
like biological effects (Park et al. 1995; Marcinkiewicz
et al. 1995b, 1998). TauCl and TauBr suppress the activity
of phagocytic cells, thereby reducing their ability to con-
sume oxygen and induce respiratory burst. In addition,
TauCl reduces the production of ROS by increasing the
expression of peroxyredoxin-1 and thioredoxin-1, the
antioxidant enzymes normally induced by the activation of
NF-E2-related factor-2 (Nrf2) (Kim et al. 2010a, b).
Moreover, TauCl and TauBr, in a similar, dose-dependent
manner, significantly enhanced in vitro the expression of
heme-oxygenase-1 (HO-1) in various cells (Olszanecki and
Marcinkiewicz 2004; Olszanecki et al. 2008; Kim et al.
2010a, b; Marcinkiewicz et al. 2009). The induction of HO-1
plays an especially important role in tissue homeostasis,
as the products of HO-1-mediated heme degradation reg-
ulate important biological processes including oxidative
stress and inflammation (Wagener et al. 2003). In addition,
HO-1 reduces synthesis of proinflammatory heme proteins
such as COX-2 and iNOS (Ryter et al. 2002). Therefore,
one may speculate that at a site of inflammation, TauCl
10 J. Marcinkiewicz, E. Kontny
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and/or TauBr will induce HO-1 in neighboring non-acti-
vated cells to protect them against oxidative stress (Fig. 5).
Taurine and taurine derivatives in inflammatory
diseases: their role in pathogenesis and treatment
of MPO-associated chronic inflammation
The antimicrobial and anti-inflammatory properties of
TauCl and TauBr make these agents good candidates for
clinical use, especially for local treatment of infectious/
inflammatory diseases (Gottardi and Nagl 2010;
Marcinkiewicz 2009). So far, the therapeutic efficacy of these
agents has been shown in acne vulgaris, external otitis,
purulently coated crural ulcerations and keratoconjuncti-
vitis (Gottardi et al. 2005, 2007; Marcinkiewicz et al. 2008;
Nagl et al. 2000a, b, 2003; Neher et al. 2007). Moreover, it
has been suggested that TauCl may be of potential benefit
as adjunctive local therapy in periodontal diseases
(Mainnemare et al. 2004). In contrast to the successful topical
therapies mentioned above, rapid degradation of TauCl and
TauBr in the blood limits their systemic application
(Martini et al. 2012). As systemic therapy with taurine
haloamines seems to be impossible, an alternative, novel
strategy may be to administer taurine itself as a prodrug.
Taurine supplementation may be predicted to enhance local
formation of TauCl or TauBr, as exogenous taurine will
react with endogenous HOCl/HOBr. Such strategies may
be effective in inflammatory conditions associated with
local infiltration of neutrophils, for example chronic
sinusitis, inflammatory bowel disease and rheumatoid
arthritis. So far, the beneficial effect of such strategy has
been documented in experimental colitis treated with
5-aminosalicyltaurine (taurine conjugated with 5-ASA)
(Kim et al. 2006; Joo et al. 2009), in dextran sulfate sodium
(DSS)-induced experimental colitis in mice attenuated by
dietary taurine supplementation (Shimizu et al. 2009) and
in collagen-induced arthritis treated with taurolidine
(Marcinkiewicz et al. 2006a, b). The precise mechanism
underlying the beneficial effects of the dietary taurine
supplementation is still unclear and remains to be
explained.
In conclusion, both in vitro and clinical studies clearly
indicate that both, taurine and taurine derivatives, may find
their place in the therapy for various topical infections as
well as chronic inflammatory diseases. In the next section,
we will discuss the role of MPO–halide system products,
namely TauCl in the pathogenesis of rheumatoid arthritis,
the best studied model of inflammatory disease in our
laboratories.
Taurine and taurine derivatives in rheumatoid arthritis
(RA) and collagen-induced arthritis (CIA)
Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune disorder affecting approximately 1 % of the popu-
lation and leading eventually to joint deformation,
dysfunction and disability in most diseased individuals.
The etiology and pathogenesis of RA are not fully under-
stood. However, genetic (e.g., genes encoding HLA-DR
molecules containing shared epitopes) and environmental
factors (e.g., Porphyromonas gingivalis infection) are
generally accepted as participating in disease development,
while repeated activation of innate immunity and deregu-
lated adaptive immunity are thought to contribute to
inflammation chronicity and self-tolerance breakdown
(Gregersen et al. 1987; Detert et al. 2010; Gierut et al.
2010; Scherer and Burmester 2011). Numerous cytokines,
released primarily by cells that accumulate in the synovium
(e.g., synoviocytes, infiltrating leucocytes), play a funda-
mental role in these pathological processes.
Novel biological therapies (cytokine antagonists, B cell
depletion, T cell co-stimulatory blockers) markedly
improved RA patients’ clinical outcomes, but impressive
efficacy is only reached in about half of them (Scott 2012).
Therefore, great efforts are made to indicate the new
therapeutic targets.
Pathological processes in rheumatoid arthritis joints
In a normal joint, the lining layer of the joint cavity (syno-
vium) is composed of intimal lining and sublining formed by
cells submerged in a bed of extracellular matrix (ECM).
Macrophage-like (MfLS) and fibroblast-like (FLS) synovi-
ocytes are present in the synovial intimal lining, where
MfLS clear the joint from microorganisms and cellular
debris, while FLS synthesize ECM and synovial fluid
components. Rheumatic joints are characterized by synovial
Fig. 5 Association of taurine with the antioxidant network: a
redundancy of the immune system. Taurine haloamines, the products
of MPO–halide system, function as a physiological link between
cysteine pathway and the heme-oxygenase-1 system (HO-1)
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membrane inflammation (synovitis) and progressive dam-
age to the articular cartilage and subchondral bone (Firestein
2009; Bartok and Firestein 2010). The number of MfLS and
FLS rises dramatically and the intimal lining expands from
1–2 cells depth to a depth of up to 10–20 cells. Both types of
rheumatoid synoviocytes display a highly activated pheno-
type and represent the major source of locally synthesized
pro-inflammatory factors and enzymes degrading connec-
tive tissue. Moreover, synoviocytes form niches for infil-
trating immune cells. By secretion of soluble factors as well
as direct cell-to-cell interaction via adhesion molecules,
synoviocytes support survival and differentiation of T and B
lymphocytes into pathogenic Th17 subset and plasma cells,
respectively. Lymphocytes and dendritic cells massively
infiltrate the sublining layer and form ectopic lymphoid
tissue, where autoantibodies are produced. Neutrophils pass
through the synovium and accumulate in RA synovial fluid,
where their number is extremely high, reaching up to
5 9 109 cells. It is well known that neutrophils recruited
into the site of inflammation generate a large number of
highly reactive oxidants, including hypochlorous acid
(HOCl). This highly reactive oxidant is immediately con-
sumed and thus inactivated by reaction with the thiol groups
of cellular proteins and proteins originating from engulfed
pathogens, as well as by transferring of the active chlorine to
amino groups. Neutrophils contain a large amount of tau-
rine, which represents about 50 % of the cellular amino acid
pool. Therefore, this dominant free amino acid is the key
molecule able to trap HOCl. Reaction of HOCl with taurine
results in the formation of taurine chloramine (TauCl),
endowed with potent anti-inflammatory properties, as
described above. Due to prolonged activation, neutrophils
accumulating in rheumatoid synovial fluid exhibit features
indicative of partial functional ‘‘exhaustion’’. Importantly,
these cells generate less TauCl in vitro than their peripheral
blood counterparts, suggesting that the local concentration
of TauCl in RA joints is probably too low to exert anti-
inflammatory effects (Kontny et al. 2002). Thus, diminished
local generation of TauCl may contribute to more complex
immunoregulatory disturbances related to the chronic
course of inflammatory response in RA joints.
As a result of the above events, rheumatoid synovium
transforms to a hyperplastic, invasive tissue. At the carti-
lage–bone interface, this expansive tissue, called pannus,
invades the cartilage and erodes into the bone. Due to their
unique invasive properties and production of huge amount
of proteases, FLS are the primary effectors of cartilage
degradation. Progressive bone damage results from
resorption of this tissue by osteoclasts and its inefficient
restoration by osteoblasts (Schett et al. 2011).
We have recently reported that also rheumatoid articular
adipose tissue (AAT) is also highly reactive and upon
stimulation secretes considerable amounts of pro-
inflammatory (IL-1b, IL-6, IL-8, TNF-a) and anti-inflam-
matory (IL-1 receptor antagonist—IL-1Ra) cytokines as
well as classical adipokines (leptin, adiponectin). More-
over, we found this tissue to release biologically active
factors that intensify the pathogenic activities of rheuma-
toid FLS. Thus, AAT should be considered a novel
important contributor to the pathological processes taking
place in the RA joints (Kontny et al. 2012).
Taurine chloramine normalizes pathogenic functions
of rheumatoid FLS
Among numerous factors secreted by FLS, VEGF and IL-8
recruit immune cells and support angiogenesis, PGE2
mediates vascular phase of inflammatory response and
osteoclastic bone resorption, while IL-6 exerts pleiotropic
effects, e.g., supports differentiation of T helper lympho-
cytes into Th17 subset, participates in bone loss and con-
tributes to systemic symptoms. In vitro studies revealed that
at physiologically relevant concentrations (200–500 lM),
TauCl inhibits synthesis of these factors by several
mechanisms: (1) acting at the transcriptional level, (2)
diminishing DNA-binding activity of NFjB and AP-1
transcription factors or (3) up-regulating heme-oxygenase-1
(Kontny et al. 1999, 2000, 2003a, b, 2007; Mu _z et al. 2008).
Another taurine derivative with potential immunoregula-
tory activity, taurine bromamine (TauBr), is less effective in
normalization of these pro-inflammatory rheumatoid FLS
properties (Kontny et al. 2007). Moreover, in these cells
TauCl down-regulates also expression of collagenases
(MMP-1, MMP-13) that play a dominant destructive role in
RA (Kim et al. 2007, 2010a, b). Furthermore, TauCl inhibits
proliferation of RA FLS and renders these cells more sen-
sitive to death (Kontny et al. 2006a, b). Thus, in vitro TauCl
dampens several activities of rheumatoid FLS relevant to
the contribution of these cells to local pathological pro-
cesses, i.e., inflammation support, joint destruction and
synovial hyperplasia.
Interestingly, neither taurine alone nor sulfoacetalde-
hyde, a product of TauCl decomposition, exerts such sup-
pressive effects on RA FLS (Kontny et al. 2003c). Thus,
the unique activities of TauCl arise from its oxidative
properties and selective modification of molecules impli-
cated in cellular signal transduction pathways (Kontny
et al. 2000; Kim et al. 2007; Mu _z et al. 2008).
Taurine chloramine exerts immunomodulatory effect
on the secretory activity of rheumatoid joint-associated
adipose tissue
We have recently reported that not only synovium but also
articular adipose tissue, organized into the largest Hoffa
infrapatellar fat pad and three smaller fat pads, is a rich
12 J. Marcinkiewicz, E. Kontny
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source of adipokines and other factors that participate in
local pathological processes characteristic for RA (Kontny
et al. 2012). In patients with osteoarthritis, articular adipose
tissue is infiltrated by immune cells (monocytes, granulo-
cytes, T lymphocytes) (Klein-Wieringa et al. 2011). The
activity of cells present in the rheumatoid synovium is
supported not only by locally produced cytokines and
growth factors, but also by direct cell-to-cell interactions.
Thus, the inhibitory effect of TauCl on isolated FLS does
not entirely reproduce in situ circumstances. To mimic in
vivo conditions, we examined the effect of TauCl on the
secretory activity of these joint tissues. Tissue specimens of
articular adipose tissue (AAT; n = 35–63), periarticular
subcutaneous adipose tissue (ScAT; n = 19–25) and
synovial membrane (SM; n = 17–25) were obtained from
knee joint of patients (60F/3 M) with established RA (RA
stages III–IV) at the time of total joint surgery, performed
as a normal part of clinical care. Subcutaneous adipose
tissue was taken from the site of the suture. All patients
gave their informed consent and the study was approved by
the Institute of Rheumatology Ethics Committee. The
mean (range) patient’s age and disease duration was 55.3
(26–68) and 17 (6–34) years, respectively. Tissue prepa-
ration and cultures were performed as described previously
(Kontny et al. 2012). Tissue explants (100 mg/ml) were
cultured in Dulbecco’s modified Eagle medium (DMEM/
50 lg/ml gentamicin/100 mg/ml kanamycin) alone, or
stimulated for 18 h with 1 lg/ml of lipopolysaccharide
from Escherichia coli 055:B5 (LPS, Difco, Detroit, MI,
USA) in the presence or absence of 500 lM TauCl. The
concentrations of selected pro- and anti-inflammatory
cytokines and classical adipokines in culture supernatants
were measured by specific ELISA, as described previously
(Kontny et al. 2012). IL-10 concentrations were measured
using commercially available set (eBioscience, San Diego,
CA, USA). Taurine chloramine (N-chlorotaurine sodium
salt), was a gift from prof. Waldemar Gottardi and prof.
Marcus Nagl from the Division of Hygiene and Medical
Microbiology, Innsbruck Medical University, Austria. Data
were analyzed using Statistica vol. 7.0 software. The
Wilcoxon test was applied to evaluate the effect of LPS and
LPS ? TauCl. Differences were considered significant for
*p \ 0.05, **p \ 0.01 and ***p \ 0.001.
As shown in Figs. 6 and 7, both AAT and ScAT pro-
duced spontaneously smaller amounts of cytokines than
SM, but cytokine release from all tested tissues rose sig-
nificantly in the presence of LPS, known to activate cells
via toll-like receptor 4. We used ScAT as a control tissue,
but unexpectedly it responded to LPS treatment similarly to
AAT, showing that adipose tissue, at least from these
locations, was highly reactive to this pro-inflammatory
stimulus. In LPS-treated adipose explant cultures, the
addition of TauCl significantly inhibited the production of
IL-6, TNF-a and IL-8 (% of inhibition was &60, 25 and
26 %, respectively). However, in equivalent SM cultures,
only the secretion of IL-6 and IL-8 was diminished (by
23–25 %), but the reduction of IL-8 release did not reach
statistical significance. By contrast, in all tissue cultures,
LPS-triggered release of anti-inflammatory IL-10 was not
significantly affected upon TauCl treatment (Fig. 6).
Interleukin 1b is another pro-inflammatory cytokine
which plays a critical role in RA pathogenesis. The bio-
logical activity of IL-1b is counteracted by IL-1Ra, but for
successful blockade a large molecular excess (100-fold to
1,000-fold) of IL-1Ra is required (Gabay et al. 2010). As
shown in Fig. 7, all tested tissues secreted spontaneously
higher amounts of IL-1Ra than IL-1b. However the
IL-1Ra/IL-b ratio was higher in AAT and ScAT than in
SM cultures, suggesting that in adipose tissue IL-1b
activity is better controlled. In all tissue cultures, LPS
markedly elevated both IL-1b and IL-1Ra release, leading
to a dramatic decrease of IL-1Ra/IL-1b ratio. In the pres-
ence of TauCl, significantly reduced secretion of both
IL-1b and IL-1Ra was observed and thus IL-1Ra/IL-1b
ratio was not restored (Fig. 7).
It has been suggested that also classical adipokines also
participate in RA pathogenesis, but their role is still con-
troversial. Leptin is structurally classified as a member of
the long-chain helical cytokine family, which includes
several pro-inflammatory cytokines, e.g., IL-6 and IL-12.
Both pro- and anti-inflammatory properties of leptin have
been described (Stofkova 2009; Neumann et al. 2011).
Adiponectin structurally belongs to the collagen super-
family and shares homologies with the collagens, com-
plement factors and TNF-a. Adiponectin has effects in a
number of different tissues, e.g., it counteracts insulin
resistance in muscle, reduces atherosclerosis, as well as
prevents the deleterious effects of TNF-a on endothelial
cells by reducing adhesion molecule expression and
inflammation (Gustafson 2010). In contrast in RA, adipo-
nectin appears to demonstrate mostly pro-inflammatory
and pro-destructive effects (Frommer et al. 2010; Neumann
et al. 2011). Adiponectin exists in several forms (globular
and multimers of high and low molecular weight) that
differ in biological activities (Gustafson 2010). Unfortu-
nately, the relevance of these adiponectin forms to RA
pathological processes is unknown.
Interestingly, the expression and release of adipokines is
reciprocally regulated by inflammatory stimuli. Acute
inflammation and pro-inflammatory cytokines (TNF-a, IL-
1, IL-6) positively regulate leptin expression and its circu-
lating levels, whereas long-term exposition to IL-1 or TNF-a
exerts negative effects. By contrast, the same pro-inflam-
matory cytokines are potent inhibitors of adiponectin gene
expression or protein secretion (Stofkova 2009). As shown
in Fig. 8, spontaneous secretion of leptin and adiponectin
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Fig. 6 Effect of TauCl on pro-
and anti-inflammatory cytokine
release from articular adipose
tissue (AAT), subcutaneous
(ScAT) adipose tissue and
synovial membrane (SM)
explants. Tissue explants were
cultured for 18 h in 37 C in
culture medium alone (control;
white bars) or treated with LPS
(1 lg/ml) in the absence (black
bars) or presence of TauCl
(500 lM) (gray bars), then
cytokine concentrations in
culture supernatants were
measured by ELISA. Values are
the mean and SEM of 35–53
(AAT), 20–25 (ScAT) or 14–24
(SM) experiments. *Indicates
statistically significant
differences between untreated
and treated cultures; #Indicates
statistically significant
differences between LPS-
versus LPS? TauCl-treated
cultures; *,#p \ 0.05;
**,##p \ 0.01; ***,###p \ 0.001
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from all tested tissues was similar. In adipose explant cul-
tures, LPS significantly up-regulated leptin release, and
addition of TauCl counteracted the LPS effect, while in SM
cultures this adipokine secretion was not affected by the
treatment. By contrast to leptin, LPS failed to exert any
effect on the release of adiponectin. However, in the pres-
ence of TauCl, all tissues secreted significantly more
adiponectin than both untreated or LPS-treated explants.
Based on the above findings, we report for the first time
that TauCl is a potent inhibitor of LPS-triggered pro-
inflammatory cytokine (IL-1b, IL-6, IL-8, TNF-a) secretion
by joint-associated adipose tissues. Although TauCl exerted
weaker inhibitory effect on SM secretory activity, suggest-
ing that this compound has limited capability for termina-
tion of synovitis, down-regulation of IL-6 and IL-1b was
observed. This is an important finding, as TNF-a, IL-1b and
IL-6 all play a critical role in RA pathogenesis and are potent
activators of cells present in SM. For this reason, therapy of
RA by neutralization of these cytokines by biological drugs
is being pursued (Scott 2012). Unfortunately, TauCl
reduced IL-1Ra release. Due to this effect, residual IL-1b
could not be controlled efficiently. However, in all tested
tissues, TauCl did not inhibit the production of IL-10, a
cytokine of known anti-inflammatory properties. Therefore,
Fig. 7 Effect of TauCl on
IL-1b and IL-1Ra release from
articular adipose tissue (AAT),
subcutaneous (ScAT) adipose
tissue and synovial membrane
(SM) explants. Explanations as
in Fig. 1. Values are the mean
and SEM of 37–41 (AAT),
19–23 (ScAT) or 17–18 (SM)
experiments
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it is likely that the net local effect of TauCl is anti-inflam-
matory. Moreover, TauCl modifies classical adipokine
secretion by inhibiting leptin and enhancing adiponectin
release. As the role of these adipokines in RA pathology is
far from clear, the net effect of this TauCl action on local
pathological processes is unpredictable at the moment.
Nevertheless, the present results expand the spectrum of
known anti-inflammatory activities of TauCl and give fur-
ther support to considering this compound as a promising
candidate for RA treatment. However, it should be under-
lined that the above effects observed upon TauCl treatment
cannot be attributed only to the direct action of this com-
pound, because TauCl may react with the culture medium
components, resulting in the formation of other chloram-
ines. Thus, the contribution of the newly formed chloram-
ines and their decomposition products cannot be excluded.
Taurine chloramine in collagen-induced arthritis (CIA)
There are reports showing that administration of TauCl
improves the course of arthritis in various experimental
animal models. Therapeutic benefits have been ascribed to
both anti-inflammatory and connective tissue protective
action of this compound. For example, intraperitoneal
TauCl administration modified adjuvant-induced arthritis
in rats due to down-regulation of the inflammatory
mediators (histamine and oxygen radical species) genera-
tion (Wojtecka-Łukasik et al. 2005). On the other hand, in
septic arthritis induced by intra-articular injection of a
single dose of Staphylococcus aureus, locally administered
TauCl exerted an inhibitory effect on the development of
bone and cartilage damage in the infected joint, but no
beneficial effects were observed when bacteria and TauCl
were administered systemically (Verdrengh and Tarkowski
2005). Collagen-induced arthritis (CIA) is an experimental
model of RA, studied extensively to elucidate the patho-
genic mechanisms of the disease and to identify potential
therapeutic targets. In genetically susceptible (DBA 1/J)
mice, the disease can be induced by immunization with
native type II collagen in adjuvant. We have previously
shown that systemic administration of TauCl either delayed
CIA onset or significantly reduced the incidence of the
disease, depending on whether TauCl therapy is applied
early (after primary immunization) or late (after booster
immunization) during the CIA course, respectively
(Kwas´ny-Krochin et al. 2002). Thus, we concluded that
systemic application of TauCl could not alleviate the
symptoms of arthritis, but may prevent CIA development.
Recently, others (Wang et al. 2011) have reported that
TauCl administered in the same way significantly attenu-
ated the severity of CIA symptoms, i.e., synovial inflam-
mation, cartilage damage and bone erosion. Moreover, in
Fig. 8 Effect of TauCl on the
release of classical adipokines
from articular adipose tissue
(AAT), subcutaneous (ScAT)
adipose tissue and synovial
membrane (SM) explants.
Explanations as in Fig. 1.
Values are the mean and SEM
of 54 (AAT), 20–23 (ScAT) or
25–28 (SM) experiments
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the joints of TauCl-treated mice, the number of osteoclasts
was reduced and in vitro TauCl inhibited osteoclasto-
genesis, supporting the idea that this compound exerts
protective effect on the bone. Although the precise mech-
anisms underlying TauCl inhibition of CIA are not fully
understood and require further studies, the above data
support the proposal that TauCl may be a useful candidate
for complementary arthritis treatment. However, to
improve therapeutic effectiveness, the stability of TauCl
should be increased. Recently, C-methylated derivatives of
TauCl with better stability at room temperature have been
obtained (Low et al. 2009; Shiau et al. 2008). In addition, a
synthetic derivative of taurine—bis(1,1-dioxoperhydro-
1,2,4-thiabiazin-4-yl)methane, named taurolidine (TRD)—
is another potential candidate for RA therapy. Owing to its
bactericidal, anti-inflammatory, antiangiogenic and antitu-
mor properties, TRD has been used in the treatment of
patients with peritonitis, sepsis or gastrointestinal and
nervous system tumors (Schneider et al. 2005; Willatts
et al. 1995; McCourt et al. 2000). In several European
countries, TRD is currently licensed for intraperitoneal use
for the treatment of peritonitis, and clinical trials evaluating
TRD potential antineoplastic benefits are currently under-
way (Neary et al. 2010). The mechanism of TRD action is
not fully understood. Taurolidine is in vivo degraded to
methylol-containing products, which exert antibacterial,
antiendotoxin and antiadherence activities, and taurine,
which is devoid of such properties. It is likely that in vivo
TRD-originated taurine may react with HOCl to produce
anti-inflammatory TauCl, but TRD can exert anti-inflam-
matory effect also by other mechanisms (Willatts et al.
1995; Marcinkiewicz et al. 2006a, b; Neary et al. 2010).
Importantly, intraperitoneal treatment with TRD reduced
the incidence of CIA in mice, while intra-articular appli-
cation of TRD resulted in amelioration of ovalbumin-
induced arthritis in rabbits (Marcinkiewicz et al. 2007).
Summary
• The fundamental role of taurine in the immune system
is related to its antioxidant properties. Taurine protects
tissues from oxidative stress associated with the
pathology of various inflammatory diseases.
• Taurine, the component (or modulator) of the myelo-
peroxidase–halide system of leukocytes, reacts with
HOCl/HOBr to produce taurine haloamines (TauCl/
TauBr), which are less toxic milder oxidants, but retain
antimicrobial and anti-inflammatory properties.
• Taurine and taurine haloamines are components of
innate immunity. The physiological functions of TauCl/
TauBr are associated with the MPO–halide system of
neutrophils.
In conclusion, both in vitro and in vivo studies as well as
clinical trials give support to consider taurine and taurine
derivatives as potential drugs in human medicine, including
infectious and chronic inflammatory disease. However,
further studies are necessary to improve their therapeutic
effectiveness, especially in the treatment of biofilm-asso-
ciated infections.
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